The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Faubion, William A.; Loftus, Edward V.; Harmsen, William S.; Zinsmeister, Alan R.; Sandborn, William J.

doi:10.1053/gast.2001.26279

Cited by 1,055 publications

(715 citation statements)

References 25 publications

Supporting

Mentioning

641

Contrasting

Unclassified

Order By: Relevance

“…Four patients only had proctitis and one patient was Baron grade 0 on sigmoidoscopy. A decision was taken (18) 5 (8) before unblinding to include these in the analysis. They were distributed across all three treatment groups.…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…3 There is no evidence from controlled trials to suggest the optimum length of treatment course or steroidtapering regimen but corticosteroids in moderate dosage have been shown to be no better than placebo at keeping patients relapse-free long-term; 4 so they are conventionally tapered off completely according to clinical response over about 2-3 months. [5][6][7] Nevertheless, it has been reported that 22% of patients may remain steroid dependent 1 year later, 8 when systemic side effects become even more problematic.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Rhodes

Robinson

Beales

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Patient Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Rhodes

Robinson

Beales

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…However, its toxicity and low capacity to maintain remission are still reasons for concern (23) . The early need for steroids to control symptoms may be a negative prognostic marker for CD outcomes (1,8) . In the present study, the concomitant use of CS at the beginning of ADA therapy was observed in 42% of the sample.…”

Section: Discussionmentioning

confidence: 99%

ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN’S DISEASE: results of a Latin American single-center observational study

Kotze¹,

Abou-Rejaile²,

Uiema³

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

Context Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn’s disease patients are scarce. Objectives The objective of this study was to outline clinical remission rates after 12 months of adalimumab therapy for Crohn’s disease patients. Methods Retrospective, single-center, observational study of a Brazilian case series of Crohn’s disease patients under adalimumab therapy. Variables analyzed: demographic data, Montreal classification, concomitant medication, remission rates after 1, 4, 6 and 12 months. Remission was defined as Harvey-Bradshaw Index ≤4, and non-responder-imputation and last-observation-carried-forward analysis were used. The influence of infliximab on remission rates was analyzed by Fischer and Chi-square tests (P<0.05). Results Fifty patients, with median age of 35 years at therapy initiation, were included. Remission rates after 12 months of therapy were 54% under non-responder-imputation and 88% under last-observation-carried-forward analysis. After 12 months, remission on patients with previous infliximab occurred in 69.23% as compared to 94.59% in infliximab-naïve patients (P = 0.033). Conclusions Adalimumab was effective in maintaining clinical remission after 12 months of therapy, with an adequate safety profile, and was also more effective in infliximab naïve patients.

show abstract

“…Среди пациентов, леченных глюкокортикостероидами, лишь у 44% наблюдается стойкая ремиссия в течение первого года, в то время как у 36% формируется стероидозависимость и у 20% стероидорезистентность [12]. У больных ЯК, впервые леченных стероидными гормонами, только у 49% наблюдался пролонгированный ответ, у 22% развилась стероидозависимость, а у 29% возникает необходимость в колэктомии из-за резистентности к лечению [13]. Развитие тяжелых осложнений язвенного колита, оперативные вмешательства, выход на инвалидность лиц молодого возраста диктуют необходимость поиска новых решений в подходе к терапии.…”

Section: сложности в леченииunclassified

Stem cells therapy in inflammatory bowel disease

Рахметова

Orazbayeva

2017

J CLIN MED KAZ

View full text Add to dashboard Cite

The article analyzes the experience of applying various stem cell pools in the treatment of inflammatory diseases of the colon. Basic and clinical studies on properties of mesenchymal stem cells and clinical effects of various technologies for their use conducted held in recent years allows to consider the mesenchymal stem cells transplantation as a new and promising direction in the treatment of ulcerative colitis.Key words: Inflammatory bowel disease, mesenchymal stem cell, transplantation, regenerative medicine. ТҰЖЫРЫМДАМАМақалада тоқ ішектің ісіп қызару ауруларын емдеуде бағаналық жасушалардың әртүрлі популяциясын қолдану тәжірибесіне талдау жасалды. Мезенхималдық бағаналық жасушалардың қасиетін және оларды пайдаланудың әртүрлі технологияларының клиникалық әсерін зерделеу бойынша соңғы жылдары өткізілген іргелі және клиникалық зерттеулер мезенхималдық бағаналық жасушаларды трансплантаттауды ойық жаралы колитті емдеудегі жаңа және перспективалық бағыт ретінде қарауға мүмкіндік береді.Негізгі сөздер: ішектің ісіп қызаруы, мезенхималдық бағаналық жасушалар, трансплантаттау, регенеративті медицина. ПРИМЕНЕНИЕ СТВОЛОВЫХ КЛЕТОК В ЛЕЧЕНИИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КИШЕЧНИКА Рахметова В. С. Оразбаева А. Б.Отдел гастроэнтерологии и гепатологии, АО «Национальный научный медицинский центр», Астана, Казахстан.РЕЗЮМЕ В статье проанализирован опыт применения различных популяций стволовых клеток в лечении воспалительных заболеваний толстого кишечника. Фундаментальные и клинические исследования по изучению свойств мезенхимальных стволовых клеток и клинических эффектов различных технологий их применения, проведенные за последние годы, позволяют рассматривать трансплантацию мезенхимальных стволовых клеток как новое и перспективное направление в лечении язвенного колита.Ключевые слова: воспалительные заболевания кишечника, мезенхимальные стволовые клетки, трансплантация, регенеративная медицина.

show abstract

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

Cited by 1,055 publications

References 25 publications

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN’S DISEASE: results of a Latin American single-center observational study

Stem cells therapy in inflammatory bowel disease

Contact Info

Product

Resources

About